PL2435023T3 - Kompozycje długodziałających antagonistów receptorów muskarynowych i długo działających agonistów receptora beta-2-adrenergicznego do dostarczania do płuc oraz powiązane sposoby i systemy - Google Patents

Kompozycje długodziałających antagonistów receptorów muskarynowych i długo działających agonistów receptora beta-2-adrenergicznego do dostarczania do płuc oraz powiązane sposoby i systemy

Info

Publication number
PL2435023T3
PL2435023T3 PL10721258T PL10721258T PL2435023T3 PL 2435023 T3 PL2435023 T3 PL 2435023T3 PL 10721258 T PL10721258 T PL 10721258T PL 10721258 T PL10721258 T PL 10721258T PL 2435023 T3 PL2435023 T3 PL 2435023T3
Authority
PL
Poland
Prior art keywords
long
acting
compositions
systems
receptor agonists
Prior art date
Application number
PL10721258T
Other languages
English (en)
Polish (pl)
Inventor
Reinhard Vehring
Michael Steven Hartman
Adrian Edward Smith
Vidya B. Joshi
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2435023(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics, Inc. filed Critical Pearl Therapeutics, Inc.
Publication of PL2435023T3 publication Critical patent/PL2435023T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10721258T 2009-05-29 2010-05-28 Kompozycje długodziałających antagonistów receptorów muskarynowych i długo działających agonistów receptora beta-2-adrenergicznego do dostarczania do płuc oraz powiązane sposoby i systemy PL2435023T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17

Publications (1)

Publication Number Publication Date
PL2435023T3 true PL2435023T3 (pl) 2017-06-30

Family

ID=42269864

Family Applications (6)

Application Number Title Priority Date Filing Date
PL16164849T PL3111927T3 (pl) 2009-05-29 2010-05-28 Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
PL16164845T PL3106149T3 (pl) 2009-05-29 2010-05-28 Kompozycje do płucnego dostarczania długo-działających antagonistów muskarynowych i długo-działających agonistów receptora beta-2 adrenergicznego oraz powiązane sposoby i układy
PL10721258T PL2435023T3 (pl) 2009-05-29 2010-05-28 Kompozycje długodziałających antagonistów receptorów muskarynowych i długo działających agonistów receptora beta-2-adrenergicznego do dostarczania do płuc oraz powiązane sposoby i systemy
PL10727553T PL2435025T3 (pl) 2009-05-29 2010-05-28 Dostarczanie substancji czynnych do dróg oddechowych
PL10727551T PL2435024T3 (pl) 2009-05-29 2010-05-28 Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
PL16164844T PL3111926T3 (pl) 2009-05-29 2010-05-28 Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL16164849T PL3111927T3 (pl) 2009-05-29 2010-05-28 Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
PL16164845T PL3106149T3 (pl) 2009-05-29 2010-05-28 Kompozycje do płucnego dostarczania długo-działających antagonistów muskarynowych i długo-działających agonistów receptora beta-2 adrenergicznego oraz powiązane sposoby i układy

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL10727553T PL2435025T3 (pl) 2009-05-29 2010-05-28 Dostarczanie substancji czynnych do dróg oddechowych
PL10727551T PL2435024T3 (pl) 2009-05-29 2010-05-28 Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
PL16164844T PL3111926T3 (pl) 2009-05-29 2010-05-28 Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego

Country Status (32)

Country Link
US (11) US9463161B2 (fr)
EP (6) EP3111926B1 (fr)
JP (10) JP5873013B2 (fr)
KR (7) KR20120015334A (fr)
CN (6) CN102458364B (fr)
AR (3) AR076806A1 (fr)
AU (3) AU2010253776B2 (fr)
BR (3) BRPI1011220B1 (fr)
CA (3) CA2763936C (fr)
CY (8) CY1118030T1 (fr)
DK (6) DK3111927T3 (fr)
ES (6) ES2589135T3 (fr)
FR (1) FR19C1040I2 (fr)
HK (6) HK1169307A1 (fr)
HR (6) HRP20161098T1 (fr)
HU (8) HUE047834T2 (fr)
IL (3) IL216466B (fr)
LT (8) LT3111927T (fr)
LU (2) LUC00124I2 (fr)
ME (1) ME03631B (fr)
MX (4) MX350163B (fr)
NL (1) NL300995I2 (fr)
NO (2) NO2019026I1 (fr)
PH (1) PH12017500778A1 (fr)
PL (6) PL3111927T3 (fr)
PT (6) PT3111926T (fr)
RU (5) RU2580315C3 (fr)
SI (6) SI3111927T1 (fr)
SM (3) SMT201600326B (fr)
TW (9) TWI546094B (fr)
WO (3) WO2010138868A2 (fr)
ZA (4) ZA201108275B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
CN104324366B (zh) 2005-09-14 2016-10-05 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (fr) 2008-06-20 2020-03-10 Mannkind Corporation Appareil interactif pour l'etablissement en temps reel d'un profil des efforts d'inhalation
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
BRPI1011220B1 (pt) * 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
RU2571331C1 (ru) * 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012158166A1 (fr) * 2011-05-17 2012-11-22 Pearl Therapeutics, Inc. Compositions, procédés et systèmes d'administration par voie respiratoire d'au moins deux agents actifs
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
JP6267685B2 (ja) * 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
RS60985B1 (sr) * 2013-01-28 2020-11-30 Incozen Therapeutics Pvt Ltd Postupci za lečenje autoimunih, respiratornih i upalnih poremećaja putem inhalacije roflumilast n-oksida
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
SG11201505556VA (en) 2013-01-31 2015-08-28 Prosonix Ltd Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
JP6564708B2 (ja) * 2013-03-04 2019-08-21 ベザン ヘルスケア ルクセンブルク エスエーアールエルＢｅｓｉｎｓ Ｈｅａｌｔｈｃａｒｅ Ｌｕｘｅｍｂｏｕｒｇ Ｓａｒｌ 担体粒子に結合した活性物質ナノ粒子を含む乾燥医薬組成物
CN105209013B (zh) * 2013-03-14 2019-04-26 诺华股份有限公司 喷雾干燥制剂经喷雾混合的脱非晶化
CA2905542C (fr) * 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Procedes et systemes de conditionnement de matieres cristallines particulaires
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
CA2912927A1 (fr) * 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, procedes & systemes pour l'administration par voie respiratoire d'au moins trois agents actifs
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
PE20160543A1 (es) * 2013-10-07 2016-06-05 Teva Branded Pharmaceutical Products Randd Inc Inhalador de polvo seco que contiene fluticasona y salmeterol
CN105263473A (zh) * 2013-11-22 2016-01-20 梯瓦优质制药产品研发股份有限公司 可吸入药物
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2015148905A1 (fr) 2014-03-28 2015-10-01 Mannkind Corporation Utilisation d'insuline à action ultrarapide
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
KR20170057451A (ko) * 2014-10-01 2017-05-24 에이엘에스 마운틴 엘엘씨 비이온성 계면 활성제와 함께 아스피린, 메트포르민 및 세로토닌을 포함하는 약학 조성물
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (fr) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Compositions pharmaceutiques comprenant de l'arformotérol et du glycopyrronium
WO2017108917A1 (fr) 2015-12-22 2017-06-29 Astrazeneca Ab Compositions pharmaceutiques pour une utilisation dans le traitement des bronchopneumopathies chroniques obstructives
CN108883079A (zh) * 2016-03-15 2018-11-23 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
US20190269703A1 (en) * 2016-05-17 2019-09-05 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
WO2018002779A1 (fr) 2016-06-30 2018-01-04 Philip Morris Products S.A. Particules de nicotine
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
ES2970740T3 (es) * 2017-10-09 2024-05-30 Pearl Therapeutics Inc Unidad de administración de aerosol
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
CN112789033A (zh) * 2018-10-02 2021-05-11 学校法人名城大学 吸入粉末剂、其评价方法及其用途
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (fr) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Composition d'aérosol stable pour inhalation comprenant du glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112804991B (zh) * 2019-06-27 2022-03-11 广州谷森制药有限公司 含富马酸福莫特罗和阿地溴铵的可吸入溶液制剂
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
CN113274596A (zh) * 2020-02-20 2021-08-20 奇斯药制品公司 包含缓冲药物制剂的加压定量吸入器
CN115666513A (zh) * 2020-05-18 2023-01-31 奥瑞克索股份公司 用于药物递送的新颖药物组合物
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (fr) * 2020-07-16 2022-01-20 Tbd Pharma Llc Solution de dexaméthasone pour le traitement d'infections par le coronavirus du syndrome respiratoire aigu sévère (sars-cov-2)
WO2022148418A1 (fr) * 2021-01-08 2022-07-14 江苏恒瑞医药股份有限公司 Composition pharmaceutique pouvant être administrée par inhalateur-doseur
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
JP2024525567A (ja) 2021-07-09 2024-07-12 アストラゼネカ・ファーマシューティカルズ・リミテッド・パートナーシップ エアロゾル薬物送達のための組成物、方法および系
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
WO2023212191A1 (fr) 2022-04-28 2023-11-02 Astrazeneca Ab Combinaison d'albutérol et de budésonide pour le traitement de l'asthme
WO2024206662A1 (fr) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Formulations liquides d'indacatérol et de glycopyrronium
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
CN118787617A (zh) * 2024-09-14 2024-10-18 苏州易合医药有限公司 一种吸入粉剂及其制备方法

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (fr) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
ZA81976B (en) * 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
ATE92762T1 (de) 1989-09-08 1993-08-15 Glaxo Group Ltd Medikamente.
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
HU213401B (en) 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
DK0613371T3 (da) 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE69432224T2 (de) 1993-12-02 2003-12-04 Abbott Laboratories, Abbott Park Aerosole als darreichungsform mit cfc-freiem treibmittel
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
DE69502179D1 (de) 1994-02-09 1998-05-28 Kinerton Ltd Verfahren zur trocknung eines materials aus einer lösung
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
PL320856A1 (en) * 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
WO1996032096A1 (fr) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Preparation pharmaceutique en poudre a dispersibilite accrue
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
EP1369414A1 (fr) * 1996-11-11 2003-12-10 Christian R. Noe Arylcycloalkyls hydroxyesters énantiomériquement purs, procédé pour leur préparation et leur utilisation comme modulateurs de récepteurs muscariniques
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
PL208480B1 (pl) 1997-03-20 2011-05-31 Schering Corp System dozujący
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
DK1019022T4 (da) * 1997-09-29 2010-11-08 Novartis Ag Perforerede mikropartikler og fremgangsmåde til anvendelse deraf
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO1999044624A2 (fr) 1998-03-05 1999-09-10 Senju Pharmaceutical Co., Ltd. Composition pharmaceutique pour la prophylaxie et la therapie de maladies associees a des modifications cytopathiques des tissus du fond de l'oeil
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
EP2266548B1 (fr) * 1998-11-13 2020-05-20 Jagotec AG Poudre sèche pour inhalation
GB9912639D0 (en) * 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
KR20010099865A (ko) 1998-12-22 2001-11-09 프란시스 제이 메이어 기도 질병 치료용 화합물과 그의 치료 방법 및 기도약물의 전달 방법
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
WO2000061108A1 (fr) 1999-04-14 2000-10-19 Glaxo Group Limited Preparation pharmaceutique en aerosol
US20100197719A1 (en) 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ATE371490T1 (de) 1999-06-30 2007-09-15 Nektar Therapeutics Verfahren und system zur herstellung von trockenem pulver mittels sprühtrocknung
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
NZ500555A (en) * 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
DK1666028T3 (da) * 1999-10-29 2010-06-21 Novartis Ag Tørre pulversammensætninger med forbedret dispersitet
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP1274433A1 (fr) 2000-04-13 2003-01-15 Innovata Biomed Limited Medicaments contenant du formoterol et de la fluticasone, destines au traitement de troubles respiratoires
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002014293A1 (fr) 2000-08-15 2002-02-21 Carsten Berg Sels d'ammonium quaternaire de 1,2-benzisothiazoline 3-un. preparation et utilisation en tant que biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
WO2002043702A2 (fr) * 2000-11-30 2002-06-06 Vectura Limited Compositions pharmaceutiques pour inhalation
EP2283817B1 (fr) * 2000-11-30 2016-05-18 Vectura Limited Procédé de préparation de particules destinées à être utilisées dans une composition pharmaceutique
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
SK286394B6 (sk) 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
EP1372751A1 (fr) * 2001-03-30 2004-01-02 Laboratoires Genevrier Neo-tissu cartilagineux greffable
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
EP1511500A4 (fr) * 2002-06-12 2009-04-29 Epigenesis Pharmaceuticals Llc Combinaison des agents anti-muscariniques et des steroides non-glucocorticoides
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
DE60311665T2 (de) 2002-08-23 2007-10-25 Schering Corp. Pharmazeutische zusammensetzungen
JP2006503865A (ja) 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
US6942821B2 (en) * 2002-10-15 2005-09-13 Cryovac, Inc. Process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger
EP1452179A1 (fr) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
WO2005000267A2 (fr) 2003-05-28 2005-01-06 Nektar Therapeutics Produit pharmaceutique formule comprenant un principe actif insoluble dans l'eau
WO2004110450A1 (fr) 2003-06-16 2004-12-23 Altana Pharma Ag Composition comprenant un surfactant pulmonaire et un inhibiteur des pde5 pour le traitement de maladies pulmonaires
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
JP2007500146A (ja) 2003-07-28 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータ受容体刺激薬及び抗コリン作用薬を含有する吸入用医薬品
JP2007500150A (ja) 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とステロイドとの併用剤及び吸入により呼吸障害を治療するためのその使用
PL1651270T3 (pl) 2003-07-29 2007-06-29 Boehringer Ingelheim Int Leki do inhalacji zawierające betamimetyki i środki przeciwcholinergiczne
JP2007500676A (ja) 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
EP1925293A3 (fr) 2003-10-20 2010-01-13 Schering Corporation Compositions d'aérosol pharmaceutique
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
SE0303270L (sv) 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
AU2004311478A1 (en) 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
PL1718336T3 (pl) 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego
RU2440813C2 (ru) * 2004-02-06 2012-01-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
WO2005077339A1 (fr) 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Procede de preparation de sol stable constitue d'ingredients pharmaceutiques et d'hydrofluorocarbone consistant a melanger ledit sol, puis a le transferer dans un contenant
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US20080214481A1 (en) * 2004-06-18 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Methods of Treatment of Endobronchial Infections
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
WO2006100453A1 (fr) 2005-03-24 2006-09-28 Sosei R & D Ltd. Sels de glycopyrronium et leur application thérapeutique
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
EP1879571A1 (fr) 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Combinaison de medicaments a inhaler contenant un betamimetique et un steroide en plus d'un anticholinergique
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2609429A1 (fr) 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Nouvelles combinaisons medicamenteuses pour le traitement de maladies respiratoires
CA2611907A1 (fr) 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Inhibiteurs mrp iv pour le traitement de maladies respiratoires
CN101262846A (zh) 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
WO2007009164A1 (fr) 2005-07-15 2007-01-25 Eiffel Technologies Limited Procede de formation de particules
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2632780C (fr) 2005-12-21 2013-11-12 Meda Pharma Gmbh & Co. Kg Combinaison de r,r-glycopyrrolate, de rolipram et de budesonide pour le traitement de maladies inflammatoires
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
CA2641604A1 (fr) * 2006-02-09 2007-08-23 Schering Corporation Formulations pharmaceutiques
CA2653105A1 (fr) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Nouvelles combinaisons de medicaments relatives au traitement de maladies respiratoires
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (fr) * 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
KR20090121338A (ko) 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
EP1964564A1 (fr) * 2007-04-19 2008-09-03 LAB International SRL Gestion efficace de la douleur
EP2036572A1 (fr) * 2007-09-04 2009-03-18 Novo Nordisk A/S Procédé pour le séchage d'une protéine, particule de protéine et composition pharmaceutique comprenant la particule de protéine
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
KR20100099281A (ko) * 2007-12-13 2010-09-10 노파르티스 아게 유기 화합물
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (fr) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BRPI1011220B1 (pt) 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
AU2011234751B2 (en) 2010-04-01 2016-03-17 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
JP2014504260A (ja) 2010-10-15 2014-02-20 グラクソ グループ リミテッド 集合ナノ粒子状薬物製剤、その製造及び使用
KR20140012989A (ko) 2011-02-17 2014-02-04 시플라 리미티드 글리코피롤레이트 및 베타2-효능제의 조합
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
WO2012158166A1 (fr) 2011-05-17 2012-11-22 Pearl Therapeutics, Inc. Compositions, procédés et systèmes d'administration par voie respiratoire d'au moins deux agents actifs
CA2912927A1 (fr) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, procedes & systemes pour l'administration par voie respiratoire d'au moins trois agents actifs

Also Published As

Publication number Publication date
BRPI1011229B1 (pt) 2020-10-13
LT3111927T (lt) 2020-03-25
NO2021019I1 (no) 2021-05-12
TW202114642A (zh) 2021-04-16
MX350164B (es) 2017-08-29
JP5873013B2 (ja) 2016-03-01
CN107669664A (zh) 2018-02-09
TWI539979B (zh) 2016-07-01
DK2435023T3 (en) 2016-10-24
DK3106149T3 (da) 2020-02-24
LUC00208I2 (fr) 2022-10-07
PT2435024T (pt) 2016-10-13
US20110132356A1 (en) 2011-06-09
NL300995I2 (nl) 2019-10-29
DK2435024T3 (en) 2016-10-24
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
RU2020102859A (ru) 2021-07-26
JP2015199735A (ja) 2015-11-12
US20170071850A1 (en) 2017-03-16
JP2018048150A (ja) 2018-03-29
JP6876734B2 (ja) 2021-05-26
HUS2100018I1 (hu) 2021-06-28
US20180125776A1 (en) 2018-05-10
CA2763936A1 (fr) 2010-12-02
HUE031283T2 (hu) 2017-07-28
HRP20161102T1 (hr) 2016-11-04
AR076621A1 (es) 2011-06-22
KR20170104003A (ko) 2017-09-13
BRPI1011220A2 (pt) 2016-03-15
IL216468A0 (en) 2012-01-31
KR20190049943A (ko) 2019-05-09
RU2016107464A3 (fr) 2019-08-19
ME03631B (fr) 2020-07-20
CY1118034T1 (el) 2017-05-17
ZA201108275B (en) 2023-04-26
US8808713B2 (en) 2014-08-19
CN107669664B (zh) 2020-07-10
SMT201600326B (it) 2016-11-10
CN107412212A (zh) 2017-12-01
EP3106149B1 (fr) 2019-11-20
PT3106149T (pt) 2020-02-19
CY1118040T1 (el) 2017-05-17
EP3111926A1 (fr) 2017-01-04
RU2016117972A3 (fr) 2019-09-27
HK1218867A1 (zh) 2017-03-17
HUS1900031I1 (hu) 2019-07-29
JP2017222706A (ja) 2017-12-21
AU2010253950C1 (en) 2015-09-17
PL2435025T3 (pl) 2017-08-31
PL3111927T3 (pl) 2020-06-29
AU2010253776B2 (en) 2015-01-22
IL216467A0 (en) 2012-01-31
ES2593429T3 (es) 2016-12-09
CN102596176A (zh) 2012-07-18
US10716753B2 (en) 2020-07-21
NL300995I1 (fr) 2019-06-24
EP3111927A1 (fr) 2017-01-04
LTPA2019014I1 (lt) 2019-07-10
MX2011012684A (es) 2012-05-23
TWI646980B (zh) 2019-01-11
IL216467B (en) 2018-12-31
JP5873012B2 (ja) 2016-03-01
ZA201208102B (en) 2013-09-25
RU2015151358A3 (fr) 2019-07-29
ES2592536T3 (es) 2016-11-30
CA2763939A1 (fr) 2010-12-02
SI2435025T1 (sl) 2016-10-28
EP2435024B1 (fr) 2016-07-06
JP5823383B2 (ja) 2015-11-25
NO2019026I1 (no) 2019-06-13
US20190307676A1 (en) 2019-10-10
PL2435024T3 (pl) 2017-01-31
HRP20200166T1 (hr) 2020-05-15
JP6348645B2 (ja) 2018-06-27
ZA201208101B (en) 2013-07-31
WO2010138884A3 (fr) 2011-04-21
RU2016117972A (ru) 2018-10-29
HK1169307A1 (zh) 2013-01-25
MX350163B (es) 2017-08-29
FR19C1040I2 (fr) 2020-07-31
US9463161B2 (en) 2016-10-11
WO2010138862A3 (fr) 2011-04-14
IL216466A0 (en) 2012-01-31
CN102753152B (zh) 2015-09-23
JP6189356B2 (ja) 2017-08-30
HK1244669A1 (zh) 2018-08-17
ES2774367T3 (es) 2020-07-20
JP2012528199A (ja) 2012-11-12
EP2435023A2 (fr) 2012-04-04
RU2713404C2 (ru) 2020-02-05
KR101926060B1 (ko) 2018-12-06
TWI695723B (zh) 2020-06-11
LT2435025T (lt) 2016-09-26
EP2435025A2 (fr) 2012-04-04
TW201808372A (zh) 2018-03-16
DK3111927T3 (da) 2020-03-09
EP2435024A2 (fr) 2012-04-04
AU2010253950A1 (en) 2011-12-08
WO2010138868A3 (fr) 2011-04-28
LT3106149T (lt) 2020-03-10
TWI632926B (zh) 2018-08-21
PT2435025T (pt) 2016-11-11
MX2011012783A (es) 2012-06-28
CN105193773A (zh) 2015-12-30
DK2435025T3 (en) 2016-10-24
HUE031229T2 (en) 2017-06-28
JP2012528200A (ja) 2012-11-12
ZA201208100B (en) 2013-07-31
CN102753152A (zh) 2012-10-24
HK1169026A1 (zh) 2013-01-18
CY2019031I2 (el) 2019-11-27
DK3111926T3 (da) 2020-03-02
RU2011154148A (ru) 2013-07-10
TWI633898B (zh) 2018-09-01
AU2010253776A1 (en) 2011-11-24
LT2435024T (lt) 2016-09-26
RU2580315C3 (ru) 2021-06-18
HUE047803T2 (hu) 2020-05-28
CY2021012I2 (el) 2021-10-15
TW201109049A (en) 2011-03-16
EP2435025B1 (fr) 2016-07-06
ES2772253T3 (es) 2020-07-07
TW201936174A (zh) 2019-09-16
TW201642836A (zh) 2016-12-16
KR20120015334A (ko) 2012-02-21
AU2010253770A1 (en) 2011-11-24
JP6492124B2 (ja) 2019-03-27
IL216466B (en) 2018-08-30
HUE047834T2 (hu) 2020-05-28
EP3106149A1 (fr) 2016-12-21
ES2589135T3 (es) 2016-11-10
HRP20200260T1 (hr) 2020-05-29
TW201109051A (en) 2011-03-16
LTPA2021511I1 (fr) 2021-06-25
TWI717511B (zh) 2021-02-01
KR20120026075A (ko) 2012-03-16
LT2435023T (lt) 2016-09-26
JP2016041713A (ja) 2016-03-31
US20110135737A1 (en) 2011-06-09
LTC2435024I2 (fr) 2022-06-27
SI3106149T1 (sl) 2020-07-31
RU2751771C2 (ru) 2021-07-16
RU2580315C2 (ru) 2016-04-10
WO2010138862A2 (fr) 2010-12-02
LT3111926T (lt) 2020-03-25
US20170112759A1 (en) 2017-04-27
BRPI1011220B1 (pt) 2020-03-10
LUC00124I1 (fr) 2019-06-13
CN107412212B (zh) 2021-01-22
JP6169639B2 (ja) 2017-07-26
SI3111927T1 (sl) 2020-08-31
BRPI1011508A2 (pt) 2016-03-22
JP2018008942A (ja) 2018-01-18
WO2010138884A2 (fr) 2010-12-02
KR20170070274A (ko) 2017-06-21
PL3106149T3 (pl) 2020-06-01
TW201919730A (zh) 2019-06-01
EP2435023B1 (fr) 2016-07-06
CN102458364B (zh) 2016-11-02
JP2015187108A (ja) 2015-10-29
US20110023876A1 (en) 2011-02-03
BRPI1011229A2 (pt) 2016-03-15
SMT201600329B (it) 2016-11-10
CN102596176B (zh) 2017-09-19
SI3111926T1 (sl) 2020-07-31
PL3111926T3 (pl) 2020-06-29
IL216468B (en) 2018-12-31
TW201700123A (zh) 2017-01-01
AR076807A1 (es) 2011-07-06
HK1247095A1 (zh) 2018-09-21
HRP20200298T1 (hr) 2020-06-12
CY1118030T1 (el) 2017-05-17
CN102458364A (zh) 2012-05-16
MX2020004077A (es) 2020-07-29
CY2021012I1 (el) 2021-10-15
EP3111926B1 (fr) 2019-12-11
TWI707700B (zh) 2020-10-21
RU2011154083A (ru) 2013-07-10
CY2019031I1 (el) 2019-11-27
CA2763941A1 (fr) 2010-12-02
KR20120034631A (ko) 2012-04-12
LTC2435025I2 (lt) 2021-02-10
US20150017247A1 (en) 2015-01-15
KR101748892B1 (ko) 2017-06-19
RU2016107464A (ru) 2018-11-22
TWI792140B (zh) 2023-02-11
JP2012528792A (ja) 2012-11-15
CA2763936C (fr) 2017-10-03
AR076806A1 (es) 2011-07-06
MX337126B (es) 2016-02-12
WO2010138868A2 (fr) 2010-12-02
SMT201600327B (it) 2016-11-10
LUC00124I2 (fr) 2019-12-27
CN105193773B (zh) 2018-12-11
RU2011152960A (ru) 2013-07-10
AU2010253950B2 (en) 2014-12-04
US20190038548A1 (en) 2019-02-07
KR101976107B1 (ko) 2019-05-09
SI2435023T1 (sl) 2016-10-28
HK1169027A1 (zh) 2013-01-18
FR19C1040I1 (fr) 2020-07-31
HUE029532T2 (en) 2017-03-28
PT3111927T (pt) 2020-03-03
US20110132357A1 (en) 2011-06-09
CY1122749T1 (el) 2021-03-12
CY1122807T1 (el) 2021-05-05
HUE047823T2 (hu) 2020-05-28
EP3111927B1 (fr) 2019-12-11
AU2010253770B9 (en) 2015-02-12
TWI546094B (zh) 2016-08-21
PT3111926T (pt) 2020-02-28
JP2019108369A (ja) 2019-07-04
MX2011012685A (es) 2012-06-12
PH12017500778A1 (en) 2018-01-22
BRPI1011229B8 (pt) 2021-05-25
HRP20161098T1 (hr) 2016-10-21
KR20180130602A (ko) 2018-12-07
RU2586297C2 (ru) 2016-06-10
TW201109050A (en) 2011-03-16
US20210186861A1 (en) 2021-06-24
SI2435024T1 (sl) 2016-10-28
HRP20161101T1 (hr) 2016-11-04
AU2010253770B2 (en) 2014-12-11
ES2774391T3 (es) 2020-07-20
CY1122732T1 (el) 2021-03-12

Similar Documents

Publication Publication Date Title
HUE031283T2 (hu) Nyújtott hatású muszkarin antagonisták és nyújtott hatású béta 2 adrenerg receptor agonisták pulmonáris beadására alkalmas készítmények és ezekkel kapcsolatos eljárások és rendszerek
HRP20190417T1 (hr) Diamidni spojevi s aktivnošću antagonista muskarinskog receptora i agonista beta 2 adrenergičkog receptora
HK1187045A1 (en) Buprenorphine analogs as opioid receptor agonists and or antagonists
PL2259774T3 (pl) Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
HK1212987A1 (zh) 具有毒蕈鹼受體拮抗劑和β 腎上腺素能受體激動劑活性的化合物
EP2423194A4 (fr) NOUVEL AGONISTE DU RÉCEPTEUR béta DE L'HORMONE THYROÏDIENNE
HK1197240A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities 2 m3
EP2563123A4 (fr) Nouveaux agonistes du récepteur bêta 3 adrénergique
IL232477A0 (en) New cyclohexylamine derivatives possessing the activities of beta 2-adrenergic agonist and muscarinic 3m antagonist
EP2427194A4 (fr) Agonistes des récepteurs bêta-3-adrénergiques dérivés de pyrrolidine
IL209264A0 (en) Heteroaromatic monoamides as orexinin receptor antagonists
IL218823A0 (en) Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
HK1159083A1 (en) Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
EP2595483A4 (fr) Nouveaux agonistes du récepteur 3-adrénergique dérivés de la pyrrolidine
EP2443111A4 (fr) Dérivés de 1,2,4-oxadiazole, leurs compositions pharmaceutiques et leur utilisation en tant qu'agonistes du récepteur 1 du sphingosine-1-phosphate
EP2632457A4 (fr) Nouveau dérivé de pyrrolidine dérivé d'agonistes des récepteurs bêta-3 adrénergiques